Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07425509 · ClinicalTrials.gov registry record · NA
Evaluation of a Stannous Fluoride Dentifrice for Control of Oral Malodor
A NA study of Oral Malodor (Halitosis), sponsored by Church & Dwight Company.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT07425509: Completed NA study of Oral Malodor (Halitosis), sponsored by Church & Dwight Company.
NCT07425509 is a NA study of Oral Malodor (Halitosis) that has completed, run by Church & Dwight Company. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07425509, a NA study of Oral Malodor (Halitosis), has completed, sponsored by Church & Dwight Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
This single-center, randomized, double-blind, two-treatment crossover clinical study evaluated the safety and efficacy of a stannous fluoride-containing dentifrice compared with a sodium fluoride control dentifrice for the control of intrinsic oral malodor. Adult subjects brushed twice daily with each product during separate treatment periods following standardized wash-out periods. Oral malodor was assessed using trained organoleptic judges applying a validated Odor Intensity (OI) scale at baseline and multiple post-treatment time points.
Conditions Studied
Interventions
- DRUG Sodium Fluoride Dentifrice
- DRUG Stannous Fluoride Toothpaste (SnF)
Study Locations (1)
Indiana
- Salus Research, Inc. - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2024-11-04 |
| Phase | NA |
What the finished NCT07425509 record still lists
NCT07425509 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Oral Malodor (Halitosis) appearing as the primary indexed condition, and to 2 interventions - of which Sodium Fluoride Dentifrice is the first listed.
NCT07425509 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT07425509 about?
NCT07425509 is a clinical study titled "Evaluation of a Stannous Fluoride Dentifrice for Control of Oral Malodor". This single-center, randomized, double-blind, two-treatment crossover clinical study evaluated the safety and efficacy of a stannous fluoride-containing dentifrice compared with a sodium fluoride control dentifrice for the control of intrinsic oral malodor. Adult subjects brushed twice daily with ea...
What is the current status of trial NCT07425509?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2024-09-09. Estimated completion is 2024-11-04.
What conditions does trial NCT07425509 study?
This clinical trial studies the following conditions: Oral Malodor (Halitosis).
What interventions are being tested in trial NCT07425509?
The interventions under investigation include: Sodium Fluoride Dentifrice (DRUG), Stannous Fluoride Toothpaste (SnF) (DRUG).
Who is sponsoring clinical trial NCT07425509?
This trial is sponsored by Church & Dwight Company, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07425509 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07425509's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI